文献速递神经免疫神经肌肉病神经重症与神经感染

免疫检查点抑制剂神经系统不良事件系统综述

Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review.
PubMed 文献 · Neurology · 2021-03-02

神经肌肉疾病报告(75%)多于中枢神经系统疾病(25%),最常见为肌炎(32%),肌无力综合征死亡率最高(28%)。

要点

  • 神经肌肉不良事件占75%,肌炎最常见(32%)。
  • 肌无力综合征抗体阳性率59%,死亡率最高(28%)。
  • 抗PD-1/PD-L1更常见于肌无力综合征(86%)。

核心结论

  • 免疫检查点抑制剂相关神经系统不良事件以神经肌肉疾病为主,肌无力综合征死亡率最高。

主要发现

  • 神经肌肉疾病报告319/428(75%),中枢神经系统疾病109/428(25%)。
  • 最常见类型为肌炎136/428(32%)、吉兰-巴雷综合征及其他周围神经病94/428(22%)、肌无力综合征58/428(14%)、脑炎56/428(13%)。
  • 肌无力综合征抗体阳性33/56(59%,p < 0.001),死亡率最高(28%)。
  • 抗PD-1/PD-L1更常见于肌无力综合征(50/58,86%,p = 0.005),较少见于脑膜炎(2/13,15%,p < 0.001)和颅神经病(13/31,42%,p = 0.005)。
  • 抗CTLA-4更常见于脑膜炎(8/13,62%,p < 0.001),较少见于脑炎(2/56,4%,p = 0.009)和肌炎(12/136,9%,p = 0.01)。

临床怎么用

  • 神经科与肿瘤科医生可依据这些特征早期识别和诊治免疫检查点抑制剂相关神经系统不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define the clinical characteristics, management, and outcome of neurologic immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). METHODS: Systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: A total of 694 articles were identified. Two hundred fifty-six articles, with 428 individual patients, met the inclusion criteria. Reports regarding neuromuscular disorders (319/428, 75%) were more frequent than those on CNS disorders (109/428, 25%). The most common n-irAEs reports were myositis (136/428, 32%), Guillain-Barré syndrome and other peripheral neuropathies (94/428, 22%), myasthenic syndromes (58/428, 14%), encephalitis (56/428, 13%), cranial neuropathies (31/428, 7%), meningitis (13/428, 3%), CNS demyelinating diseases (8/428, 2%), and myelitis (7/428, 2%). Other CNS disorders were detected in 25/428 (6%) patients. Compared with the whole sample, myasthenic syndromes were significantly more Ab positive (33/56, 59%; p < 0.001). Anti-programmed cell death protein 1/programmed cell death ligand 1 was more frequent in myasthenic syndromes (50/58, 86%; p = 0.005) and less common in meningitis (2/13, 15%; p < 0.001) and cranial neuropathies (13/31, 42%; p = 0.005). Anti-cytotoxic T-lymphocyte antigen-4 ICIs were more frequent in meningitis (8/13, 62%; p < 0.001) and less common in encephalitis (2/56, 4%; p = 0.009) and myositis (12/136, 9%; p = 0.01). Combination of different ICIs was more frequent in cranial neuropathies (12/31, 39%; p = 0.005). Melanoma was more frequent in patients with peripheral neuropathies (64/94, 68%; p = 0.003) and less common in encephalitis (19/56, 34%; p = 0.001). The highest mortality rate was reached in myasthenic syndromes (28%). CONCLUSION: Considering the increasing use of ICI therapy in the forthcoming future, this information can be valuable in assisting neurologists and oncologists in early n-irAEs diagnosis and treatment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Marini A, Bernardini A, Gigli GL, et al. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology. 2021. PMID: 33653902. doi:10.1212/WNL.0000000000011795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。